Fangda represents Summa Equity in selling HyTest to Mindray for EUR 532 million
Tell others about this press release
The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.
Fangda Partners acted as PRC legal counsel to Summa Equity in selling HyTest, a leading producer of high-performance antibodies and antigens, to Mindray for total consideration of EUR 532 million. The transaction was closed on September 22, 2021. The Fangda team on this deal was led by partner Andrew ZHANG, and the team members include Francisco Li and Cynthia Zhan. Fangda handled PRC legal due diligence, commented on the transaction documents and advised on legal matters affecting the transaction structure from a PRC legal perspective.
Join our mailing list for legal news and alerts
Sign up